Evidence map›Paper›PMID 29106638›Full record

ArticleThe Journal of infectious diseases2017

Linking Individual Natural History to Population Outcomes in Tuberculosis.

Phillip P Salvatore, Alvaro Proaño, Emily A Kendall, Robert H Gilman, David W Dowdy

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Tuberculosis and Increased Incidence of Cardiovascular Disease: Cohort Study Using United States and United Kingdom Health Records.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  2. Cost-effectiveness of TB diagnostic technologies in Ethiopia: a modelling study.Cost effectiveness and resource allocation : C/E · 2024
    Article
  3. The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  4. Article
  5. Infectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implications.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Phillip P SalvatoreDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Alvaro ProañoLaboratorio de Investigación en Enfermedades Infecciosas, Laboratorio de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
Emily A KendallDivision of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Robert H GilmanLaboratorio de Investigación en Enfermedades Infecciosas, Laboratorio de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
David W DowdyDepartment of International Health, Baltimore, Maryland.
Johns Hopkins University · USPrisma · PEUniversidad Peruana Cayetano Heredia · PE

Funding

Translational modeling of individual- and population-level outcomes of novel tuberculosis drug regimensK08AI127908 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KENDALL, EMILY A · 2017 to 2021
$879k
Medical Research Council MR/K007467/1NIAID NIH HHS K08 AI127908
6 · The paper itself

Abstract

Background: Substantial individual heterogeneity exists in the clinical manifestations and duration of active tuberculosis. We sought to link the individual-level characteristics of tuberculosis disease to observed population-level outcomes. Methods: We developed an individual-based, stochastic model of tuberculosis disease in a hypothetical cohort of patients with smear-positive tuberculosis. We conceptualized the disease process as consisting of 2 states-progression and recovery-including transitions between the 2. We then used a Bayesian process to calibrate the model to clinical data from the prechemotherapy era, thus identifying the rates of progression and recovery (and probabilities of transition) consistent with observed population-level clinical outcomes. Results: Observed outcomes are consistent with slow rates of disease progression (median doubling time: 84 days, 95% uncertainty range 62-104) and a low, but nonzero, probability of transition from disease progression to recovery (median 16% per year, 95% uncertainty range 11%-21%). Other individual-level dynamics were less influential in determining observed outcomes. Conclusions: This simplified model identifies individual-level dynamics-including a long doubling time and low probability of immune recovery-that recapitulate population-level clinical outcomes of untreated tuberculosis patients. This framework may facilitate better understanding of the population-level impact of interventions acting at the individual host level.

Indexed as

Computer SimulationDisease Transmission, InfectiousCohort StudiesHumansTuberculosisdisease progressionmathematical modelsnatural historyspontaneous remissiontuberculosis

Identifiers

PMID29106638
PMCPMC5853266
OpenAlexW2767109468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.